InterCure Ltd. (INCR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
InterCure Ltd. (INCR) trades at $0.90 with AI Score 34/100 (Grade D). InterCure Ltd. is a pharmaceutical company focused on the research, cultivation, production, marketing, and distribution of medical cannabis products. Market cap: $48.94M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for INCR: INCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INCR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INCR: 1/1 perspectives are bearish.
InterCure Ltd. (INCR) Healthcare & Pipeline Overview
InterCure Ltd. is a vertically integrated cannabis company operating in the specialty and generic drug manufacturing sector, focusing on cultivation, production, and distribution of medical cannabis products in Israel and international markets. The company offers dried cannabis inflorescences and cannabis extract mixed with oil, while also investing in the biomed sector.
What Is the Investment Thesis for INCR?
InterCure Ltd. presents a compelling investment thesis based on its strategic positioning in the rapidly growing medical cannabis market. The company's vertically integrated operations, from cultivation to distribution, provide a competitive advantage in ensuring product quality and supply chain control. With a market capitalization of $0.04 billion, InterCure has significant growth potential as it expands its presence in Israel and international markets. Key growth catalysts include increasing acceptance and legalization of medical cannabis, expansion into new therapeutic areas, and strategic partnerships. However, investors should be aware of risks associated with regulatory changes, competition, and the company's current negative profit margin of -19.5%. The company's beta of 0.33 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
INCR Key Highlights
- Market capitalization of $0.04 billion indicates the company's current valuation in the market.
- Gross margin of 21.7% reflects the company's profitability after deducting the cost of goods sold.
- Negative profit margin of -19.5% suggests the company is currently operating at a loss.
- Beta of 0.33 indicates lower volatility compared to the overall market, suggesting a more stable investment.
- Vertically integrated operations provide control over the entire value chain, from cultivation to distribution.
Who Are INCR's Competitors?
INCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $4.17 | -1.18% | 2B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.61 | +1.67% | $8.03M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| SGIOY Shionogi & Co., Ltd. | $8.64 | -0.29% | $14.71B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INCR's Key Strengths?
- Vertically integrated operations.
- Established presence in the Israeli market.
- Expertise in cultivation and production.
- Investments in the biomed sector.
What Are INCR's Weaknesses?
- Negative profit margin.
- Limited geographic diversification.
- Reliance on the Israeli market.
- Relatively small market capitalization.
What Could Drive INCR Stock Higher?
- Increasing acceptance and legalization of medical cannabis globally.
- Potential regulatory changes in key international markets.
- Expansion into new therapeutic areas and product development.
- Strategic partnerships and acquisitions to expand market reach.
What Are the Key Risks for INCR?
- Regulatory changes and uncertainty in the cannabis market.
- Intense competition from other cannabis producers and distributors.
- Fluctuations in cannabis prices and supply chain disruptions.
- Negative public perception of cannabis and stigma associated with its use.
What Are the Growth Opportunities for INCR?
- Expansion into new therapeutic areas: InterCure can expand its product offerings to target specific medical conditions such as chronic pain, anxiety, and epilepsy. The market for cannabis-based treatments for these conditions is growing rapidly, presenting a significant opportunity for InterCure to increase its revenue and market share. The timeline for this expansion is ongoing as research and clinical trials continue to support the efficacy of cannabis in these areas. This expansion leverages InterCure's existing cultivation and production infrastructure.
- Geographic expansion into international markets: InterCure can expand its operations into new international markets where medical cannabis is legal or becoming legal. This expansion would allow the company to diversify its revenue streams and reduce its reliance on the Israeli market. The timeline for this expansion depends on regulatory changes and market conditions in each country. InterCure's expertise in cultivation, production, and distribution can be leveraged in these new markets.
- Strategic partnerships and acquisitions: InterCure can pursue strategic partnerships and acquisitions to expand its product offerings, market reach, and technological capabilities. These partnerships and acquisitions can provide access to new markets, technologies, and expertise, accelerating InterCure's growth and innovation. The timeline for these partnerships and acquisitions is opportunistic, depending on available opportunities and strategic fit. These moves can enhance InterCure's competitive position.
- Development of innovative cannabis-based products: InterCure can invest in research and development to create new and innovative cannabis-based products, such as novel formulations, delivery methods, and therapeutic applications. These new products can differentiate InterCure from its competitors and attract new customers. The timeline for this development is ongoing, as research and clinical trials are required to validate the safety and efficacy of new products. Innovation can drive long-term growth.
- Increased focus on patient education and outreach: InterCure can invest in patient education and outreach programs to increase awareness of the benefits of medical cannabis and promote its products to patients and healthcare providers. These programs can help to reduce stigma, increase acceptance, and drive demand for InterCure's products. The timeline for these programs is ongoing, as continuous efforts are needed to educate and inform patients and healthcare providers. Education can build trust and brand loyalty.
What Opportunities Does INCR Have?
- Expansion into new therapeutic areas.
- Geographic expansion into international markets.
- Strategic partnerships and acquisitions.
- Development of innovative cannabis-based products.
What Threats Does INCR Face?
- Regulatory changes and uncertainty.
- Intense competition in the cannabis market.
- Fluctuations in cannabis prices.
- Negative public perception of cannabis.
What Are INCR's Competitive Advantages?
- Vertically integrated operations provide control over the entire value chain.
- Established presence in the Israeli medical cannabis market.
- Expertise in cultivation, production, and distribution of medical cannabis products.
What Does INCR Do?
InterCure Ltd. was established in 1994 and is headquartered in Herzliya, Israel. The company has evolved into a prominent player in the medical cannabis industry, focusing on the research, cultivation, production, marketing, and distribution of medical cannabis products. InterCure operates primarily in Israel and is expanding its international presence. Its core offerings include dried cannabis inflorescences and cannabis extract mixed with oil, catering to patients with various medical conditions. InterCure distinguishes itself through a vertically integrated business model, controlling the entire value chain from cultivation to distribution, ensuring product quality and consistency. The company also invests in the broader biomed sector, exploring opportunities in related healthcare fields. InterCure's strategic focus on the medical cannabis market positions it to capitalize on the increasing acceptance and legalization of cannabis for medical purposes globally. With 320 employees, the company continues to innovate and expand its product offerings to meet the evolving needs of patients and healthcare providers.
What Products and Services Does INCR Offer?
- Researches medical cannabis products.
- Cultivates medical cannabis plants.
- Produces medical cannabis extracts and oils.
- Markets medical cannabis products to patients and healthcare providers.
- Distributes medical cannabis products in Israel and internationally.
- Invests in the biomed sector.
How Does INCR Make Money?
- Vertically integrated operations from cultivation to distribution.
- Sales of dried cannabis inflorescences and cannabis extract mixed with oil.
- Investments in the biomed sector to diversify revenue streams.
What Industry Does INCR Operate In?
InterCure Ltd. operates within the rapidly expanding medical cannabis industry, driven by increasing acceptance and legalization of cannabis for medical purposes globally. The market is characterized by intense competition, evolving regulations, and growing demand for high-quality cannabis products. InterCure's vertically integrated business model and strategic focus on the medical market position it to capitalize on these trends. The company competes with other cannabis producers, distributors, and pharmaceutical companies in Israel and international markets. The global medical cannabis market is projected to reach billions of dollars in the coming years, presenting significant growth opportunities for InterCure.
Who Are INCR's Key Customers?
- Patients with medical conditions who are prescribed medical cannabis.
- Healthcare providers who recommend medical cannabis to their patients.
- Pharmacies and dispensaries that sell medical cannabis products.
INCR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
INCR Latest News
-
Toronto Home Sales Increase Most in Nine Months as Buyers Return
Bloomberg · May 5, 2026
-
Hon Hai Sales Grow 30% With Expansion of AI Server Business
Bloomberg · May 5, 2026
-
Consumers face more pain as companies threaten price rises
International homepage · May 5, 2026
-
Rocket Lab Unveils New High-Performance Star Tracker Optimized for Accuracy in Increased Radiation Environments
Business Insider · Apr 23, 2026
INCR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INCR.
Price Targets
Wall Street price target analysis for INCR.
INCR MoonshotScore
What does this score mean?
The MoonshotScore rates INCR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Toronto Home Sales Increase Most in Nine Months as Buyers Return
Hon Hai Sales Grow 30% With Expansion of AI Server Business
Consumers face more pain as companies threaten price rises
Rocket Lab Unveils New High-Performance Star Tracker Optimized for Accuracy in Increased Radiation Environments
Leadership: Alexander Rabinovich
CEO
Alexander Rabinovich serves as the CEO of InterCure Ltd., managing a team of 320 employees. His background includes extensive experience in the pharmaceutical and healthcare industries. He has a proven track record of leading and growing companies in highly regulated environments. His expertise spans strategic planning, operational management, and business development. He is responsible for driving InterCure's growth strategy and ensuring its compliance with regulatory requirements.
Track Record: Under Alexander Rabinovich's leadership, InterCure has expanded its presence in the Israeli medical cannabis market and pursued international expansion opportunities. He has overseen the development of new cannabis-based products and the implementation of strategic partnerships. His focus on operational efficiency and regulatory compliance has contributed to the company's growth and stability.
Common Questions About INCR (Healthcare)
What does InterCure Ltd. do?
InterCure Ltd. is a vertically integrated cannabis company that engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates primarily in Israel and internationally, offering dried cannabis inflorescences and cannabis extract mixed with oil. InterCure controls the entire value chain, from cultivation to distribution, ensuring product quality and consistency. The company also invests in the biomed sector, exploring opportunities in related healthcare fields. InterCure's strategic focus on the medical cannabis market positions it to capitalize on the increasing acceptance and legalization of cannabis for medical purposes globally.
What do analysts say about INCR stock?
Analyst coverage of InterCure Ltd. is limited, but the general sentiment is cautiously optimistic due to the company's growth potential in the medical cannabis market. Key valuation metrics, such as price-to-sales and price-to-earnings ratios, are difficult to assess due to the company's current negative profit margin. Growth considerations include the company's ability to expand into new therapeutic areas, penetrate international markets, and maintain its competitive advantage in the Israeli market. Investors should carefully consider the risks associated with regulatory changes, competition, and market volatility.
What are the main risks for INCR?
InterCure Ltd. faces several risks, including regulatory changes and uncertainty in the cannabis market, intense competition from other cannabis producers and distributors, fluctuations in cannabis prices and supply chain disruptions, and negative public perception of cannabis. Regulatory changes can impact the company's ability to operate in certain markets and introduce new compliance requirements. Intense competition can erode market share and pricing power. Fluctuations in cannabis prices and supply chain disruptions can impact profitability. Negative public perception of cannabis can limit demand and hinder growth.
What are the key factors to evaluate for INCR?
InterCure Ltd. (INCR) holds an AI score of 34/100 (low). Not financial advice.
How frequently does INCR data refresh on this page?
INCR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INCR's recent stock price performance?
InterCure Ltd. (INCR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INCR overvalued or undervalued right now?
Valuing InterCure Ltd. (INCR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying INCR?
Before investing in InterCure Ltd. (INCR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Analyst opinions and market conditions can vary.